期刊
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
卷 66, 期 4, 页码 560-574出版社
WILEY
DOI: 10.1111/1754-9485.13416
关键词
hypoxia; immune suppression; PD-1; PD-L1 blockade; radiotherapy; tumour microenvironment
资金
- Astra Zeneca
The combination of PD-1/PD-L1 blockade and radiotherapy has the potential to enhance anti-tumour immunity and improve clinical outcomes, but tumour hypoxia presents a significant challenge to the success of both therapies. Targeting tumour hypoxia with compounds that reduce hypoxia may optimize the efficacy of the combination.
Immune checkpoint inhibition with PD-1/PD-L1 blockade is a promising area in the field of anti-cancer therapy. Although clinical data have revealed success of PD-1/PD-L1 blockade as monotherapy or in combination with CTLA-4 or chemotherapy, the combination with radiotherapy could further boost anti-tumour immunity and enhance clinical outcomes due to the immunostimulatory effects of radiation. However, the synergistic combination of PD-1/PD-L1 blockade and radiotherapy can be challenged by the complex nature of the tumour microenvironment (TME), including the presence of tumour hypoxia. Hypoxia is a major barrier to the effectiveness of both radiotherapy and PD-1/PD-L1 blockade immunotherapy. Thus, targeting the hypoxic TME is an attractive strategy to enhance the efficacy of the combination. Addition of compounds that directly or indirectly reduce hypoxia, to the combination of PD-1/PD-L1 inhibitors and radiotherapy may optimize the success of the combination and improve therapeutic outcomes. In this review, we will discuss the synergistic combination of PD-1/PD-L1 blockade and radiotherapy and highlight the role of hypoxic TME in impeding the success of both therapies. In addition, we will address the potential approaches for targeting tumour hypoxia and how exploiting these strategies could benefit the combination of PD-1/PD-L1 blockade and radiotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据